Anthropic, the AI safety company backed by Amazon and Google, has acquired Coefficient Bio, a stealth biotech startup of fewer than ten people, in an all-stock deal valued at just over $400 million. [1] The company was founded eight months ago. It has no public product, no revenue, and no published research. The price works out to roughly $40 million per employee.

The deal is Anthropic's first significant acquisition and its most explicit signal that the company sees drug discovery as a primary commercial application for its Claude family of large language models. Coefficient Bio's team reportedly includes computational biologists and machine learning researchers who previously worked at Genentech and DeepMind, bringing expertise in protein folding, molecular simulation, and clinical trial design. [1]

The acquisition lands in a competitive landscape that has shifted rapidly. Google DeepMind's AlphaFold transformed structural biology. Isomorphic Labs, DeepMind's drug discovery spinout, has partnership deals with Eli Lilly and Novartis. [2] Anthropic appears to be betting that general-purpose frontier models, fine-tuned with biological domain expertise, can compete with purpose-built scientific AI systems.

The all-stock structure means Anthropic paid in equity valued at its most recent $61.5 billion valuation -- paper wealth that costs nothing unless the company goes public or is acquired. [1] For Anthropic, the real expense is attention. Every hour its best researchers spend on biology is an hour not spent on safety or capability research.

Whether this is vision or valuation froth depends on what Coefficient Bio's team builds next.

-- KENJI NAKAMURA, Tokyo